Consider researching pharmaceutical giant AbbVie (ABBV), as its drug pipeline, led by Skyrizi and Rinvoq, presents a potentially strong long-term investment. Biotechnology firm Sarepta Therapeutics (SRPT) received a direct bullish endorsement and is worth a closer look for those interested in the sector. For exposure to the popular GLP-1 weight-loss drug theme, investigate key players like Structure Therapeutics (GPCR) and Viking Therapeutics (VKTX). Highly speculative stocks like Quantum (QCI) are rallying in the current "risk-on" environment, but should be approached with extreme caution due to their high volatility. Finally, it may be wise to avoid stocks with recent poor performance and negative sentiment, such as Joby Aviation (JOBY) and Akero Therapeutics (AKRO).

Speculative "Risk-On" Stocks

• The speaker identifies a group of stocks, including Quantum and Ocklow (Oklo), as "garbage" and "risky shit" that are rallying.
• He notes this rally is happening in a "risk on" environment, where investors are buying the riskiest assets, even while the broader market (S&P 500) is down.
• He mentions he is long Quantum (QCI), but also admits to having been "very very wrong" on it in the past, highlighting his mixed experience with the stock.
• He is using deep in the money calls to trade, a strategy to get leveraged exposure to these stocks.

Takeaways

• Stocks like Quantum (QCI) and Oklo (OCLO) are presented as highly speculative, high-risk investments.
• The speaker's commentary suggests their recent price increases may be disconnected from fundamentals and driven more by market sentiment.
• Investors should approach these names with extreme caution due to their high volatility and the speaker's own characterization of them as "garbage."

AbbVie (ABBV)

• The speaker performs a detailed analysis of AbbVie, adding its drugs to a personal database he is building during the stream.
• He highlights the strength of its drug portfolio, calling Skyrizi "probably the most important medicine in the world right now."
• He also discusses other key products like Rinvoq and Botox, noting their multiple approved indications and market strength.
• The deep research and positive comments on its key drugs imply a strong interest and a potentially bullish long-term view.

Takeaways

• The speaker seems to see significant, underappreciated value in AbbVie's drug pipeline, especially its newer immunology drugs that are replacing the revenue from the older drug, Humira.
• This could be a signal for investors to conduct their own due diligence on ABBV, focusing on the growth prospects of Skyrizi and Rinvoq.

Sarepta Therapeutics (SRPT)

• The speaker makes a direct and positive comment about the stock.
• He states, "Sarepta... has done really well. I like Sarepta."

Takeaways

• This is a clear, bullish endorsement from the speaker.
• Investors interested in the biotechnology sector may want to research SRPT to understand why it might be performing well and what its future catalysts could be.

Tesla (TSLA)

• The speaker mentions a news alert that Tesla beat delivery estimates because buyers were rushing to secure expiring tax credits.
• He points out the stock's extreme intraday volatility, noting it was up earlier in the day but was down 10% intraday during the stream.

Takeaways

• TSLA stock is highly sensitive to news, especially delivery numbers and regulatory changes (like tax credits).
• Investors should be prepared for significant and rapid price swings. The discussion highlights the stock's inherent volatility.

GLP-1 Sector (Weight-Loss Drugs)

• The speaker discusses the popular GLP-1 drug sector, noting that even large pharmaceutical companies like Pfizer (PFE) are becoming more bullish on the space.
• He mentions specific companies in the sector to watch:
  • Structure Therapeutics (GPCR)
  • Viking Therapeutics (VKTX)
• He expresses some caution, noting the space is crowded by saying, "Everyone who needs a GLP has got one."

Takeaways

• The GLP-1 (weight-loss drug) trend remains a major investment theme in the biopharma industry.
• While the sector is competitive, companies like Structure (GPCR) and Viking (VKTX) are identified as key players that could be starting points for investors looking to gain exposure to this theme.

Cautionary Mentions

• The speaker reflects on some of his past investments that have not performed well.
• Joby Aviation (JOBY): He calls this investment a "real rough one" and admits to being "very very wrong" about it.
• Akero Therapeutics (AKRO): He states that it has "not exactly been a big winner."

Takeaways

• This serves as a transparent look at the speaker's own investment losses and a reminder that even experienced investors can be wrong.
• It acts as a specific warning about the risks and poor past performance associated with JOBY and AKRO.

Stocks to Avoid (According to the Speaker)

• When asked about X (formerly Twitter), the speaker gives a direct and negative opinion.
• He states, "I don't want X stock."

Takeaways

• The speaker has a clear "avoid" stance on X, suggesting he does not see it as a worthwhile investment.